Detalles de la búsqueda
1.
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
N Engl J Med
; 384(19): 1824-1835, 2021 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33440088
2.
Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
N Engl J Med
; 371(7): 635-45, 2014 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-25119609
3.
Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.
Hum Vaccin Immunother
; 17(11): 4689-4700, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34582323
4.
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Lancet Infect Dis
; 21(9): 1257-1270, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887209
5.
Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Vaccine
; 36(42): 6325-6333, 2018 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30197282
6.
Corrigendum to 'Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults'. [Vaccine 36 (2018) 6325-6333].
Vaccine
; 38(12): 2746-2747, 2020 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32061383
Resultados
1 -
6
de 6
1
Próxima >
>>